A Phase 2a, Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-1942 Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression
Latest Information Update: 04 Oct 2023
At a glance
- Drugs MK-1942 (Primary) ; Antidepressants
- Indications Major depressive disorder
- Focus Adverse reactions; Therapeutic Use
- Acronyms MK-1942-006
- Sponsors Merck Sharp & Dohme Corp.
- 26 Sep 2023 Status changed from recruiting to discontinued.
- 19 May 2023 Planned End Date changed from 5 Aug 2024 to 26 Jan 2024.
- 19 May 2023 Planned primary completion date changed from 5 Aug 2024 to 26 Jan 2024.